Results 161 to 170 of about 4,014,458 (336)
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior Disorder
Annals of Neurology, EarlyView.Objective
To determine the impact of dopamine deficiency and isolated rapid eye movement (REM) sleep behavior disorder (iRBD) on cognitive performance in early neuronal α‐synuclein disease (NSD) with hyposmia but without motor disability. Methods
Using Parkinson's Progression Markers Initiative baseline data, cognitive performance was assessed with a ...Daniel Weintraub, Anuprita R. Nair, Ryan Kurth, Michael C. Brumm, Christine Kohnen, Michele K. York, Roseanne D. Dobkin, Kenneth Marek, Caroline Tanner, Tanya Simuni, Andrew Siderowf, Douglas Galasko, Lana M. Chahine, Christopher Coffey, Kalpana Merchant, Kathleen L. Poston, Tatiana Foroud, Brit Mollenhauer, Ethan G. Brown, Karl Kieburtz, Mark Frasier, Sohini Chowdhury, Roy N. Alcalay, Aleksandar Videnovic, The Parkinson's Progression Markers Initiative +24 morewiley +1 more sourceThe Spectrum of Neurologic Phenotypes Associated With NUS1 Pathogenic Variants: A Comprehensive Case Series
Annals of Neurology, EarlyView.Objective
A growing body of evidence indicates a strong genetic overlap between developmental and epileptic encephalopathies (DEEs) and movement disorders. De novo loss‐of‐function variants in NUS1 have been recently identified in DEE cases. Herein, we report a large cohort of cases with pathogenic NUS1 variants and describe their clinical presentation Sarah M. Brooker, Maria Novelli, Robert Coukos, Neha Prakash, Walaa A. Kamel, Marta Amengual‐Gual, Mathieu Anheim, Giulia Barcia, Tanya Bardakjian, Franciska Baur, Steffen Berweck, Bigna K. Bölsterli, Melanie Brugger, Thomas Cassini, Nicolas Chatron, Brian Corner, Hormos Salimi Dafsari, Jean‐Madeleine de Sainte Agathe, Colin A. Ellis, Kimberly M. Ezell, Cendrine Foucard, Steven J. Frucht, Maria C. Garcia, Deepak Gill, Anne Guimier, Rizwan Hamid, Damià Heine‐Suñer, Peter Herkenrath, Marie Hully, Ioannis U. Isaias, Louis Januel, Chloe Laurencin, Taylor Laut, Alinoe Lavillaureix, Gaetan Lesca, Marion Lesieur‐Sebellin, Luca Magistrelli, Cecilia Marelli, Heather C. Mefford, Bryce A. Mendelsohn, Saadet Mercimek‐Andrews, Claire Miller, Shekeeb S. Mohammad, Francesca Morgante, Sirisha Nandipati, Thomas Opladen, Mahesh Padmanaban, Micaela Pauni, Gianni Pezzoli, Amelie Piton, Francis Ramond, Giulietta M. Riboldi, Christelle Rougeot‐Jung, Fernando Santos‐Simarro, Ingrid E. Scheffer, Naoual Serari, Christine M. Stahl, Ann Stembridge Kung, Susana Tarongí Sanchez, Christel Thauvin‐Robinet, Marianne Till, Christine Tranchant, Christopher Troedson, Thomas F. Tropea, Olivier Vanakker, Patricia Vega, Maxi Leona Wiese, Udo Wieshmann, Laura J. Williams, Thomas Wirth, Michael Zech, Hans Zempel, Emmanuel Roze, Vincenzo Leuzzi, Serena Galosi, Victor S. C. Fung, Gemma Carvill, Dimitri Krainc, Elizabeth Gerard, Niccolò E. Mencacci +79 morewiley +1 more sourceHospitalization, Arrest, or Discharge: Important Legal and Clinical Issues in the Emergency Evaluation of Persons Believed Dangerous to Others [PDF]
, 1982 Applebaum, Paul S., Huber, George A., Ore, Timothy M., Roth, Loren H. +3 morecore +2 more sourcesTiming of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks
Annals of Neurology, EarlyView.Objective
The objective of this study was to evaluate the timing of change of Alzheimer's disease (AD) plasma biomarkers (Aβ42/Aβ40, p‐tau217, p‐tau181, GFAP, and NfL) from six different assay platforms, alongside established AD biomarkers, using amyloid and tau positron emission tomography (PET)‐based AD progression timelines.Marta Milà‐Alomà, Duygu Tosun, Suzanne E. Schindler, Isabella Hausle, Kellen K. Petersen, Yan Li, Jeffrey L. Dage, Lei Du‐Cuny, Ziad S. Saad, Benjamin Saef, Gallen Triana‐Baltzer, David L. Raunig, Janaky Coomaraswamy, Michael Baratta, Emily A. Meyers, Yulia Mordashova, Carrie E. Rubel, Kyle Ferber, Hartmuth Kolb, Nicholas J. Ashton, Henrik Zetterberg, Erin G. Rosenbaugh, Martin Sabandal, Leslie M. Shaw, Anthony W. Bannon, William Z. Potter, for the Alzheimer's Disease Neuroimaging Initiative (ADNI), Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project Team +27 morewiley +1 more sourcePsychiatric symptoms after acute respiratory distress syndrome: a 5-year longitudinal study
Intensive Care Medicine, 2017 O. J. Bienvenu, O. J. Bienvenu, L. A. Friedman, E. Colantuoni, E. Colantuoni, V. Dinglas, Kristin A. Sepulveda, P. Mendez-Tellez, Carl Shanholz, Peter J. Pronovost, Peter J. Pronovost, D. Needham +11 moresemanticscholar +1 more sourceBlood α‐Synuclein Separates Parkinson's Disease from Dementia with Lewy Bodies
Annals of Neurology, EarlyView.Objective
Aggregation of misfolded α‐synuclein (aSyn) within the brain is the pathologic hallmark of Lewy body diseases (LBDs), including Parkinson's disease (PD), and dementia with Lewy bodies (DLB) disease. Although evidence exists for aSyn “strains,” conformations with distinct biological properties, biomarkers for PD versus DLB are lacking.George T. Kannarkat, Rebecca Zack, R. Tyler Skrinak, James F. Morley, Roseanne Davila‐Rivera, Sanaz Arezoumandan, Katherine Dorfman, Kelvin Luk, David A. Wolk, Daniel Weintraub, Thomas F. Tropea, Edward B. Lee, Sharon X. Xie, Ganesh Chandrasekaran, Virginia M.‐Y. Lee, David Irwin, Rizwan S. Akhtar, Alice S. Chen‐Plotkin +17 morewiley +1 more source